Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

Feng Gao, Bette T. Korber, Eric A. Weaver, Hua Xin Liao, Beatrice H. Hahn, Barton F. Haynes

Research output: Contribution to journalReview article

55 Scopus citations

Abstract

Genetic variation of HIV-1 represents a major obstacle for AIDS vaccine development. With the amino acid sequence divergence as high as 30% in envelopes between different subtypes among HIV-1 group M viruses, it is unlikely that cross-subtype protection will occur equally well among all subtypes. Computer programs have been used to generate 'centralized' HIV gene sequences: consensus, ancestor or center of the free. These sequences can decrease the genetic distances between the 'centralized' and wild-type gene immunogens to half of those between any wild-type immuongens to each other, Recent studies demonstrated that an artificial group M consensus env gene is equidistant from any subtype and recombinants. It is biologically functional and preserves antigenicity similar to contemporary Env proteins. Most importantly, the group M consensus Env immunogen can elicit both T- and B-cell responses to wild-type HIV-1 isolates.

Original languageEnglish (US)
Pages (from-to)S161-S168
JournalExpert Review of Vaccines
Volume3
Issue number4 SUPPL.
DOIs
StatePublished - Aug 2004
Externally publishedYes

Keywords

  • Consensus
  • Diversity
  • Immunogen
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity'. Together they form a unique fingerprint.

  • Cite this

    Gao, F., Korber, B. T., Weaver, E. A., Liao, H. X., Hahn, B. H., & Haynes, B. F. (2004). Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Review of Vaccines, 3(4 SUPPL.), S161-S168. https://doi.org/10.1586/14760584.3.4.S161